These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34205554)

  • 21. Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics.
    Lum K; Bhatti T; Holland S; Guthrie M; Sassman S
    J Law Med Ethics; 2018 Jun; 46(1_suppl):66-74. PubMed ID: 30146960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits of Incentives for Breastfeeding and Smoking cessation in pregnancy (BIBS): a mixed-methods study to inform trial design.
    Morgan H; Hoddinott P; Thomson G; Crossland N; Farrar S; Yi D; Hislop J; Moran VH; MacLennan G; Dombrowski SU; Rothnie K; Stewart F; Bauld L; Ludbrook A; Dykes F; Sniehotta FF; Tappin D; Campbell M
    Health Technol Assess; 2015 Apr; 19(30):1-522, vii-viii. PubMed ID: 25897655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.
    Morel CM; Lindahl O; Harbarth S; de Kraker MEA; Edwards S; Hollis A
    J Antibiot (Tokyo); 2020 Jul; 73(7):421-428. PubMed ID: 32203126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000-15: an analysis of pharmaceutical sales data.
    Klein EY; Milkowska-Shibata M; Tseng KK; Sharland M; Gandra S; Pulcini C; Laxminarayan R
    Lancet Infect Dis; 2021 Jan; 21(1):107-115. PubMed ID: 32717205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring payment schemes used to promote integrated chronic care in Europe.
    Tsiachristas A; Dikkers C; Boland MR; Rutten-van Mölken MP
    Health Policy; 2013 Dec; 113(3):296-304. PubMed ID: 23937868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Essential and forgotten antibiotics: An inventory in low- and middle-income countries.
    Tebano G; Li G; Beovic B; Bielicki J; Brink A; Enani MA; Godman B; Hinrichsen SL; Kibuule D; Gabriel LH; Oduyebo O; Sharland M; Singh S; Wertheim HFL; Nathwani D; Pulcini C;
    Int J Antimicrob Agents; 2019 Sep; 54(3):273-282. PubMed ID: 31260741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia.
    Coghlan R; Stephens P; Mwale B; Siyanga M
    Malar J; 2018 Nov; 17(1):444. PubMed ID: 30497504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives.
    Morel CM; Edwards SE
    J Law Med Ethics; 2018 Jun; 46(1_suppl):75-80. PubMed ID: 30146962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoting rational antibiotic use in Turkey and among Turkish migrants in Europe - implications of a qualitative study in four countries.
    Westerling R; Daryani A; Gershuni O; Czabanowska K; Brand H; Erdsiek F; Aksakal T; Uner S; Karadag Caman O; Ozcebe H; Brzoska P
    Global Health; 2020 Nov; 16(1):108. PubMed ID: 33176820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of financial incentives on the quality of health care provided by primary care physicians.
    Scott A; Sivey P; Ait Ouakrim D; Willenberg L; Naccarella L; Furler J; Young D
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008451. PubMed ID: 21901722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combating antibiotic resistance using guidelines and enhanced stewardship in Kenya: a protocol for an implementation science approach.
    Gitaka J; Kamita M; Mureithi D; Ndegwa D; Masika M; Omuse G; Ngari M; Makokha F; Mwaura P; Mathai R; Muregi F; Mwau M
    BMJ Open; 2020 Mar; 10(3):e030823. PubMed ID: 32234736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Creating a climate that catalyses healthcare innovation in the United Kingdom - learning lessons from international innovators.
    Cresswell K; Cunningham-Burley S; Sheikh A
    J Innov Health Inform; 2017 Jan; 23(4):882. PubMed ID: 28346133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the HITECH financial incentives on EHR adoption in small, physician-owned practices.
    Cohen MF
    Int J Med Inform; 2016 Oct; 94():143-54. PubMed ID: 27573322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prioritizing research areas for antibiotic stewardship programmes in hospitals: a behavioural perspective consensus paper.
    Rzewuska M; Charani E; Clarkson JE; Davey PG; Duncan EM; Francis JJ; Gillies K; Kern WV; Lorencatto F; Marwick CA; McEwen J; Möhler R; Morris AM; Ramsay CR; Rogers Van Katwyk S; Skodvin B; Smith I; Suh KN; Grimshaw JM;
    Clin Microbiol Infect; 2019 Feb; 25(2):163-168. PubMed ID: 30195471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K; McDonnell A
    Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
    Edwards SE; Morel CM
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.